PCSK9和MIF在乳腺癌中的水平及其临床意义
Serum Level and Clinical Significance of PCSK9 and MIF in Breast Cancer
DOI: 10.12677/md.2024.143050, PDF,    科研立项经费支持
作者: 慕玉东, 贺 林：西安交通大学医学院附属陕西省肿瘤医院，陕西 西安；张 涛*：西安交通大学医学院附属西安市中心医院，陕西 西安
关键词: PCSK9；MIF；乳腺癌；PCSK9； MIF； Breast Cancer
摘要: 目的：探讨PCSK9和MIF在乳腺癌中的水平及其临床意义。方法：选取从2021年1月至2022年12月在我院就诊的139例乳腺癌患者和125健康体检人员。测定血清及组织PCSK9和MIF水平，分析在乳腺癌中的相关性。结果：乳腺癌患者的血清PCSK9和MIF水平明显高于对照组(P < 0.05)；乳腺癌组织中PCSK9和MIF表达水平高于对照组，但差异无统计学意义；PCSK9与MIF表达在乳腺癌中呈正相关。结论：血清PCSK9和MIF水平与乳腺癌相关，而且PCSK9表达与MIF表达在乳腺癌中呈正相关，检测PCSK9和MIF可为乳腺癌的筛查、早期诊断及精准治疗提供新的依据。
Abstract: Objective: To investigate the relationship between the level of PCSK9 and MIF and breast cancer. Methods: From January 2021 to December 2022, 139 breast cancer patients after surgery and 125 health people as control group were elected. The levels of propotein convertase subtilisin/kexin 9 (PCSK9) and macrophage migration inhibitory factors (MIF) were measured, and analyzed the relationship in breast cancer. Results: The serum levels of PCSK9 and MIF in breast cancer patients was significantly higher than the control group (P < 0.05). The tissue levels of PCSK9 and MIF in breast cancer patients was significantly higher than breast fibroma patients, but the difference was not statistically significant. PCSK9 levels correlated positively with MIF levels in breast cancer tissue. Conclusion: The levels of PCSK9 and MIF were related to breast cancer, and PCSK9 levels correlated positively with serum MIF levels. Through monitoring the levels of PCSK9 and MIF, the methods should provide a new theoretical basis for early diagnosis and screening of breast cancer and accurate treatment.
文章引用：慕玉东, 贺林, 张涛. PCSK9和MIF在乳腺癌中的水平及其临床意义[J]. 医学诊断, 2024, 14(3): 352-357. https://doi.org/10.12677/md.2024.143050

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] 王静, 于国华, 曲桂梅. 肿瘤微环境对乳腺癌的作用[J]. 临床与病理杂志, 2023, 43(11): 2008-2014.
[3] Baron, N., Deuster, O., Noelker, C., Stüer, C., Strik, H., Schaller, C., et al. (2011) Role of Macrophage Migration Inhibitory Factor in Primary Glioblastoma Multiforme Cells. Journal of Neuroscience Research, 89, 711-717. [Google Scholar] [CrossRef] [PubMed]
[4] Baek, A.E. and Nelson, E.R. (2016) The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Hormones and Cancer, 7, 219-228. [Google Scholar] [CrossRef] [PubMed]
[5] Garcia-Estevez, L. and Moreno-Bueno, G. (2019) Updating the Role of Obesity and Cholesterol in Breast Cancer. Breast Cancer Research, 21, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[6] Leignadier, J., Dalenc, F., Poirot, M. and Silvente-Poirot, S. (2017) Improving the Efficacy of Hormone Therapy in Breast Cancer: The Role of Cholesterol Metabolism in SERM-Mediated Autophagy, Cell Differentiation and Death. Biochemical Pharmacology, 144, 18-28. [Google Scholar] [CrossRef] [PubMed]
[7] Tang, Z., Li, T., Peng, J., Zheng, J., Li, T., Liu, L., et al. (2018) PCSK9: A Novel Inflammation Modulator in Atherosclerosis? Journal of Cellular Physiology, 234, 2345-2355. [Google Scholar] [CrossRef] [PubMed]
[8] Wiciński, M., Żak, J., Malinowski, B., Popek, G. and Grześk, G. (2017) PCSK9 Signaling Pathways and Their Potential Importance in Clinical Practice. EPMA Journal, 8, 391-402. [Google Scholar] [CrossRef] [PubMed]
[9] Ward, E.M., DeSantis, C.E., Lin, C.C., Kramer, J.L., Jemal, A., Kohler, B., et al. (2015) Cancer Statistics: Breast Cancer in Situ. CA: A Cancer Journal for Clinicians, 65, 481-495. [Google Scholar] [CrossRef] [PubMed]
[10] Melvin, J.C., Holmberg, L., Rohrmann, S., Loda, M. and Van Hemelrijck, M. (2013) Serum Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses. Journal of Cancer Epidemiology, 2013, 1-12. [Google Scholar] [CrossRef] [PubMed]
[11] Hachem, A., Hariri, E., Saoud, P., Lteif, C., Lteif, L. and Welty, F. (2017) The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review. Current Cardiology Reviews, 13, 274-282. [Google Scholar] [CrossRef] [PubMed]
[12] Giugliano, R.P., Pedersen, T.R., Saver, J.L., Sever, P.S., Keech, A.C., Bohula, E.A., et al. (2020) Stroke Prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients with Stable Atherosclerosis. Stroke, 51, 1546-1554. [Google Scholar] [CrossRef] [PubMed]
[13] Zhang, S., Zhu, X., Feng, L., Li, X., Liu, X., Sun, H., et al. (2021) PCSK9 Promotes Tumor Growth by Inhibiting Tumor Cell Apoptosis in Hepatocellular Carcinoma. Experimental Hematology & Oncology, 10, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
[14] Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., et al. (2020) Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer. Nature, 588, 693-698. [Google Scholar] [CrossRef] [PubMed]
[15] Lan, H., Pang, L., Smith, M.M., Levitan, D., Ding, W., Liu, L., et al. (2010) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Affects Gene Expression Pathways Beyond Cholesterol Metabolism in Liver Cells. Journal of Cellular Physiology, 224, 273-281. [Google Scholar] [CrossRef] [PubMed]
[16] Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., et al. (2021) Circulating Tumor Cells: Biology and Clinical Significance. Signal Transduction and Targeted Therapy, 6, Article No. 404. [Google Scholar] [CrossRef] [PubMed]
[17] Pereira-Veiga, T., Schneegans, S., Pantel, K. and Wikman, H. (2022) Circulating Tumor Cell-Blood Cell Crosstalk: Biology and Clinical Relevance. Cell Reports, 40, Article 111298. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, X. and Song, E. (2022) The Theory of Tumor Ecosystem. Cancer Communications, 42, 587-608. [Google Scholar] [CrossRef] [PubMed]
[19] Galli, F., Aguilera, J.V., Palermo, B., Markovic, S.N., Nisticò, P. and Signore, A. (2020) Relevance of Immune Cell and Tumor Microenvironment Imaging in the New Era of Immunotherapy. Journal of Experimental & Clinical Cancer Research, 39, Article No. 89. [Google Scholar] [CrossRef] [PubMed]
[20] Wu, F., Fan, J., He, Y., Xiong, A., Yu, J., Li, Y., et al. (2021) Single-Cell Profiling of Tumor Heterogeneity and the Microenvironment in Advanced Non-Small Cell Lung Cancer. Nature Communications, 12, Article No. 2540. [Google Scholar] [CrossRef] [PubMed]
[21] Lippitz, B.E. (2013) Cytokine Patterns in Patients with Cancer: A Systematic Review. The Lancet Oncology, 14, e218-e228. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, N., Jiang, N., Guo, R., Jiang, W., He, Q., Xu, Y., et al. (2013) MiR-451 Inhibits Cell Growth and Invasion by Targeting MIF and Is Associated with Survival in Nasopharyngeal Carcinoma. Molecular Cancer, 12, Article No. 123. [Google Scholar] [CrossRef] [PubMed]
[23] Figueiredo, C.R., Azevedo, R.A., Mousdell, S., Resende-Lara, P.T., Ireland, L., Santos, A., et al. (2018) Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response against Metastatic Melanoma. Frontiers in Immunology, 9, Article 1132. [Google Scholar] [CrossRef] [PubMed]
[24] Kong, F., Deng, X., Kong, X., Du, Y., Li, L., Zhu, H., et al. (2018) ZFPM2-AS1, a Novel IncRNA, Attenuates the P53 Pathway and Promotes Gastric Carcinogenesis by Stabilizing MIF. Oncogene, 37, 5982-5996. [Google Scholar] [CrossRef] [PubMed]
[25] Castro, B.A., Flanigan, P., Jahangiri, A., Hoffman, D., Chen, W., Kuang, R., et al. (2017) Macrophage Migration Inhibitory Factor Downregulation: A Novel Mechanism of Resistance to Anti-Angiogenic Therapy. Oncogene, 36, 3749-3759. [Google Scholar] [CrossRef] [PubMed]
[26] Bonaventura, A., Grossi, F. and Montecucco, F. (2020) PCSK9 Is a Promising Prognostic Marker in Patients with Advanced NSCLC. Cancer Immunology, Immunotherapy, 69, 491-492. [Google Scholar] [CrossRef] [PubMed]
[27] Abdelwahed, K.S., Siddique, A.B., Mohyeldin, M.M., Qusa, M.H., Goda, A.A., Singh, S.S., et al. (2020) Pseurotin a as a Novel Suppressor of Hormone Dependent Breast Cancer Progression and Recurrence by Inhibiting PCSK9 Secretion and Interaction with LDL Receptor. Pharmacological Research, 158, Article 104847. [Google Scholar] [CrossRef] [PubMed]
[28] Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., et al. (2020) Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer. Nature, 588, 693-698. [Google Scholar] [CrossRef] [PubMed]